AlphaStreet Newsdesk powered by AlphaStreet Intelligence
Onkure Therapeutics Inc (OKUR) reported Q2 2026 basic and diluted earnings of -$0.31 per share.

Bottom line showed a net loss of $15.3M.
Wall Street consensus stands at 6 buy, 2 hold, 0 sell. The loss of $0.31 per share narrowed 72.8% from the $1.14 loss in Q2 2025.
This content is for informational purposes only and should not be considered investment advice. AlphaStreet Intelligence analyzes financial data using AI to deliver fast and accurate market information. Human editors verify content.











-1024x683.jpg)







